Tau immunotherapy for Alzheimer's disease
Abstract
Targeting pathological tau protein in Alzheimer's disease (AD) and related tauopathies has shown great potential in animal models. Given that tau lesions correlate better with the degree of dementia than do amyloid-β (Aβ) plaques, their clearance may be clinically more efficacious than removing Aβ when cognitive deficits become evident in AD. Several complementary mechanisms of antibody-mediated removal of tau aggregates are likely to act in concert and the importance of each one may depend on antibody properties, the disease, and its stage. Clinical trials of tau immunotherapy are already underway and several more are likely to be initiated in the near future.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Antibodies, including anti-tau antibodies, can enter neurons.
“However, several groups have reported that antibodies, including anti-tau antibodies, can enter neurons, and that extracellular tau might be important for the spread of tau pathology227–229.”
From Tau-targeting therapies for Alzheimer disease (2018) · cites this paper as [227]
Extracellular tau might be important for the spread of tau pathology.
“However, several groups have reported that antibodies, including anti-tau antibodies, can enter neurons, and that extracellular tau might be important for the spread of tau pathology227–229.”
From Tau-targeting therapies for Alzheimer disease (2018) · cites this paper as [227]
The citation lists haven’t been fetched yet
References 97 · Cited by 247
- Authors
- Pedersen, J. T., & Sigurdsson, E. M.
- Affiliations
- Lundbeck (Denmark) (DK)
- New York University (US)
- Corresponding author
- Pedersen, Jan Torleif
- Sigurdsson, Einar M.
- ORCID
- Sigurdsson, Einar M.
- Venue
- Trends in Molecular Medicine
- Publisher
- Elsevier BV
- Published
- 2015-06
- Volume
- 21
- Issue
- 6
- Pages
- 394-402
- ISSN
- 1471-4914 (ISSN-L)
- OpenAlex
- W2032665165
- Cited by
- 247
- References
- 97
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 14 · 2023: 9 · 2022: 21 · 2021: 23 · 2020: 27 · 2019: 26 · 2018: 44 · 2017: 37 · 2016: 30 · 2015: 7
- FWCI
- 4.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Trends in Molecular Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- NIH (NS077239, AG032611 and AG020197)
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- tau immunotherapy, Alzheimer's disease, tauopathy, tau protein, anti-tau antibodies, amyloid plaques, cognitive impairment, clinical trials, disease stage
- MeSH terms
- Alzheimer Disease, Amino Acid Sequence, Animals, Antibodies, Humans, Immunotherapy, Molecular Sequence Data, tau Proteins, Tauopathies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
